Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530758 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6533951 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3536193 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2774793 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13451331 | 0.95 | — | — | |
| SCHEMBL4761390 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL1461782 | 0.88 | — | — | |
| SCHEMBL14116863 | 0.86 | KDM4E (0.54) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL29134334 | 0.86 | KDM4E (0.42) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18677293 | 0.86 | SMN1; SMN2 (0.48) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404056-B1 | METHOD FOR PRODUCING THERMOPLASTIC ELASTOMER COMPOSITION | ZEON CORP (JP) | 2025-06-11 | — | — | EP | disclosed |
| EP-3101065-B1 | CROSS-LINKABLE NITRILE RUBBER COMPOSITION AND CROSS-LINKED RUBBER | ZEON CORP (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-12202923-B2 | Nitrile-group-containing copolymer rubber | ZEON CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-10-31 | — | — | US | disclosed |
| CN-114555660-B | Nitrile group-containing copolymer rubber | 日本瑞翁株式会社 | 2024-06-11 | — | — | CN | disclosed |
| EP-4376845-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2024-06-05 | — | — | EP | disclosed |
| EP-3305817-B2 | NITRILE GROUP CONTAINING, HIGHLY SATURATED COPOLYMER RUBBER | ZEON CORP (JP) | 2023-12-27 | — | — | EP | disclosed |
| EP-3744739-B1 | METHOD FOR PRODUCING CARBOXY GROUP-CONTAINING HYDROGENATED NITRILE RUBBER | ZEON CORP (JP) | 2023-12-27 | — | — | EP | disclosed |
| US-11639408-B2 | Nitrile group-containing copolymer rubber | ZEON CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-3604433-B1 | CROSSLINKABLE RUBBER COMPOSITION AND CROSSLINKED RUBBER OBJECT | ZEON CORP (JP) | 2023-04-19 | — | — | EP | disclosed |
| US-9458275-B2 | Cross-linkable rubber composition and cross-linked rubber | ZEON CORPORATION (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20150246991-A1 | CROSS-LINKABLE RUBBER COMPOSITION AND CROSS-LINKED RUBBER | ZEON CORPORATION (JP) | 2015-09-03 | — | — | US | disclosed |
| EP-2902437-A1 | CROSSLINKABLE RUBBER COMPOSITION AND CROSSLINKED RUBBER | Zeon Corporation (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8563559-B2 | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120088768-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-1654257-B1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | MKI67, CDK4, PGF | KDM4E 3717/4885ALDH1A1 757/4885CYP1A2 1246/4885 |
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | PDGFRB, PDGFRA, ABL1 | KDM4E 2970/4885ALDH1A1 538/4885CYP1A2 1010/4885 |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | MKI67, VEGFA, FLT1 | KDM4E 4059/4885ALDH1A1 618/4885CYP1A2 1488/4885 |
| US-20120088768-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB2 | KDM4E 4211/4885ALDH1A1 4034/4885CYP1A2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.